Finalist
Accelerating a New Era of Patient Involvement in EU Medicines Assessment
Summary of work
In 2022, the European Commission approved the new EU Regulation on Joint Health Technology Assessment (HTAR), transforming how medicines are reviewed and reimbursed across Europe.In recognition of the magnitude of this shift – and guided by insights that awareness and understanding of HTAR amongst the patient community was low – the Takeda EUCAN Oncology Patient Advocacy team developed a plan to provide education to the patient community who were actively seeking further information on the Regulation and its implementation.From the outset, the programme was designed as a stepwise journey, with shared patient community goals in mind. The central focus was to provide background and education on the Regulation and its implementation. This would help to facilitate informed patient involvement under the new HTAR framework and ensure that the patient voice is not only heard but acted upon. By working in close collaboration with the patient community and patient experts, we have moved from an early stage understanding to a sophisticated, multi-layered programme of education.
Judges’ comments
The entry from Takeda and JPA Health was strong and was a good example of “challenge accepted”. The context and outcomes were strong, with very impressive engagement and feedback. It clearly resulted in Takeda being a trusted source in the EU environment.
